Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.
Actively Recruiting
Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.
Actively Recruiting
Researchers are investigating the effects and safety of the medicine PF-07275315 for treating moderate to severe Chronic Obstructive Pulmonary Disease COPD, a lung condition that makes breathing difficult and impacts daily life. This interventional study involves adults aged 35 to 80 who have had COPD for at least 12 months and experienced at least two moderate or severe exacerbations in the past year while on stable maintenance treatment. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections at the clinic. The Phase 2 portion lasts 24 weeks with study involvement totaling about 40 weeks and includes 11 clinic visits. The Phase 3 portion lasts 52 weeks with approximately 68 weeks total involvement and 18 clinic visits. The study compares outcomes between those receiving PF-07275315 and those receiving placebo to evaluate safety and effectiveness. During the study, participants will undergo regular assessments including lung function tests such as forced expiratory volume FEV1, monitoring of exacerbation rates, symptom questionnaires, safety lab tests, electrocardiograms, and vital signs. Safety and adverse events will be closely tracked throughout the study, and participants will be followed for the full duration of their assigned phase to monitor changes and outcomes related to COPD.
Actively Recruiting
Researchers are evaluating eptinezumab to see if it reduces the number of migraine days compared to a placebo in young people aged 12 to 17 with chronic migraine. This phase 3 study focuses on adolescents who have had chronic migraine for at least six months and aims to assess the preventive treatment effects of this intravenous drug. Participants are randomly assigned to one of three groups to receive a single intravenous infusion of either eptinezumab 300 mg, eptinezumab 100 mg, or a placebo. The doses are adjusted according to each participants body weight. The study includes a 4-week screening period, followed by a 12-week double-blind treatment phase, and ends with an 8-week safety follow-up period. During the study, participants will complete headache diaries and undergo evaluations to measure changes in monthly migraine days and other migraine-related outcomes. Researchers will also monitor blood levels of eptinezumab and immune responses. The total study participation lasts approximately 24 weeks, including screening, treatment, and safety follow-up phases.
Actively Recruiting
Researchers are investigating the long-term safety of eptinezumab in children and adolescents aged 6 to 17 who have chronic or episodic migraine. This extension study involves participants who completed previous related studies and aims to continue monitoring their response to the treatment over an extended period. The study is phase 3 and evaluates the effects of eptinezumab to better understand its safety profile in this younger population. Participants will receive eptinezumab through intravenous infusions in one of two dose groups 100 mg or 300 mg, both adjusted by weight. Those who received these doses in prior studies will continue the same dose, while those previously on placebo will be randomly assigned to one of the two dose groups with equal chance. Each participant will receive three infusions at weeks 0, 12, and 24 during the open-label extension. Throughout the study, participants will undergo various assessments including tracking of adverse events, blood tests measuring eptinezumab levels and antibodies, and evaluations of migraine disability using the Pediatric Migraine Disability Assessment Questionnaire at specified weeks. The study extends up to week 44, with safety and efficacy monitoring continuing throughout, ensuring comprehensive data collection on the long-term effects of eptinezumab in this age group.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether a modified version of metaxalone 640 mg can reduce pain in adults experiencing acute low back and leg pain associated with lumbar spinal stenosis and sciatica. This phase 4, double-blind, randomized, placebo-controlled trial compares the effects of metaxalone plus standard care to a placebo in patients aged 18 to 80 years who are otherwise healthy and have newly occurring pain. Participants will be randomly assigned to one of two groups one receiving metaxalone 640 mg oral tablets every 6 hours for 7 days, and the other receiving an inactive placebo capsule on the same schedule. The study is conducted across multiple centers with a parallel design and includes a pilot phase followed by a larger randomized study. During the trial, participants will complete surveys on Day 1 before treatment and again on Day 7 to report on pain intensity, the impact of pain on physical activity, and sleep interference. The primary outcome measure is the change in the Numeric Pain Scale score from Day 1 to Day 7. Participants will be monitored for adherence and safety throughout the 7-day treatment period.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.
1-10 of 17
1